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pts, increased charge time 8 pts, device advisory 4 pts, and to preserve battery 31 pts.
Changes were made during a total of 157 visits, or a mean of 2 visits/pt (range 0-7). Con-
clusions: Programming of tachycardia and bradycardia parameters are frequently per-
formed at outpatient ICD FU. Although TTM of ICDs may be a useful adjunct for FU, it will
not completely replace office visits based on the need for individualized device repro-
gramming.
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BACKGROUND: Cardiac resynchronization therapy with defibrillators (CRT-D) has
proven efficacy and mortality benefit in heart failure patients with a wide QRS complex.
Implantation of such devices can be achieved either using transvenous coronary sinus
leads or with epicardial left ventricular leads. OBJECTIVE: To evaluate the comparative
efficacy of epicardial LV leads with transvenous CS leads, if any, on the change in LVEF
in patients receiving CRT-Ds. METHODS AND RESULTS: 130 consecutive patients
underwent implantation of a BiV ICD. The patients were evaluated for the LVEF using
transthoracic echocardiogram 1 month before the device implant and then 1-3 months
after the implantation of the device. All patients included in the study had the RV lead
placed at the apex and the LV lead positioned either transvenously in the posterior or lat-
eral branch of the CS or an epicardial LV lead placed atthe corresponding surface of the
heart at surgery. The patients were divided into two groups. Group I included 96 patients
who underwent BiV ICD implantation using a transvenous CS lead. In this group the
mean LVEF improved from 18.6+6.8% to 21.4+8.1% (p value 0.03). Group II included 34
patients with a similar device implanted using an epicardial LV lead. The LVEF in this
group improved from a mean of 17.6±5.6% to 21.9±9.5% (p value 0.02). When compared
for the mean LVEF pre and post procedure, there was no significant difference between
the two groups (p values 0.26 and 0.36, respectively). The mean rise in the LVEF in the
two groups was 1.82±5.9% in patients with CS leads and 2.4±6.1% in patients with epi-
cardial LV leads and this was not statistically significant (p value 0.3). CONCLUSIONS:
There is comparable improvement in the LVEF in patients treated with CRT-D using either
transvenous coronary sinus leads or epicardial left ventricular leads. Epicardial LV lead
placement can be safely considered for cardiac resynchronization therapy in patients
undergoing open heart surgery or subsequent to a failed CS lead placement.
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Background: Newer implantable CRT devices measure night heart rate (NHR) and heart
rate variability (HRV) on a daily basis. This retrospective analysis examined if these
device measurements were different for patients at risk for clinical events.
Methods: Heart failure decompensations were reviewed for the U.S. InSync III trial
patients. Patients in NYHA III/IV heart failure without traditional pacing indications were
enrolled. Patients were classified into three groups: 1) those with no decompensations
(No-HF), 2) those with decompensations not requiring hospitalization (Minor event), and
3) those with decompensations requiring hospitalization (Hosp). Weekly averages of
NHR and HRV were computed for the first 52 weeks post implant. Differences between
groups were tested using a repeated measures analysis.
Results: There were 126, 68, and 44 pts in the No-HF, Minor event, and Hosp groups,
respectively, with mean follow-up of 16.5 months. HRV averaged 89±26, 87±28, and
75±27 ms (p=.002, No-HF versus Hosp; p=.019, Minor versus Hosp). See figure. NHR
averaged 69±11, 70±9, and 74±11 bpm (p=.004, No-HF versus Hosp; p=.019, Minor ver-
sus Hosp). At baseline, the Hosp group had lower beta blocker usage and higher NYHA
class.
Conclusions: HRV and NHR, continuously derived from an implanted device, are differ-
ent in heart failure patients at higher risk for clinical events, suggesting that HRV and
NHR, in concert with traditional measures, may help stratify patients at risk for heart fail-
ure decompensation.
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Background: Cardiac resynchronization therapy (CRT) is a novel therapy in patients
with heart failure (HF). Weekly monitoring of mean heart rate (HR), HR range, heart rate
variability (HRV), and daily physical activity of pts with CRT has not been investigated in
detail. 
Methods: Data stored on a CRT-D (Contak-Renewal II, Guidant, USA) implanted in 54
pts (mean age 60.6± 3.8 years, QRS 149.6 ± 6.8 msec, LVEF 19± 0.9%) with NYHA
class >II despite optimal pharmacological treatment, were reviewed. Over a period of 12
weeks, changes of minimum HR (HR min), mean HR, HR range (min to max), standard
deviation of mean R-R intervals (SDANN) and degree of physical activity done by each
patient, measured by Activity Log Index (AL) of the device, were analysed.
Results: CRT-D determined a significant decrease of minimum and mean HR (66.2 ± 16
vs 58.5± 2.1 and 78.6± 18.2 vs 72.2± 2.8 bpm, respectively, p<0.04) and a marked
increase of HR range (31.1± 11.7 vs 39.7± 9.8 bpm, p< 0.006) and SDANN (63.5± 29.4
vs 88.4± 19 msec, p<0.004). Moreover, after 12 weeks of continuous pacing, AL
increased from 4.3± 1.9 to 11.2± 2.6% units (p<0.001). Changes of each parameter over
12 weeks are reported in the graph. 
Conclusions: the Contak-Renewal II device allows continuous assessment of surrogate
parameters of autonomic-nerve system activity. CRT-D provided a clear decrease of sym-
pathetic activity with an increase of parasympathetic tone. Moreover, a higher degree of
physical activity after 12 weeks of pacing was noted. 
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Background: Clinical trials have shown favorable long-term effects of angiotensin-con-
verting enzyme (ACE) inhibitors on morbidity and mortality in patients with congestive
heart failure (CHF). ACE inhibitors may affect and modify the triggering factors and sub-
strates of ventricular arrhythmias and sudden cardiac death in these patients. This study
was aimed at examining the effects of ACE inhibitors on the incidence of defibrillator
(ICD) therapy in patients with CHF secondary to idiopathic dilated cardiomyopathy
(DCM).
Methods & Results: One hundred and two patients (aged 52±16 years) with idiopathic
